Takeda, is focused on creating better health for people and a brighter future for the world, announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Hyqvia [Immune ...

(Takeda) is pleased to announce that Héma-Québec has added HyQvia ® – (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a ...

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA ® [Immune Globulin Infusion 10% (Human) with Recombinant Human ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human ...

HyQvia is approved in Canada as a replacement ... Notably, it is the only subcutaneous immune globulin infusion that offers a once-monthly administration schedule, either every three or four ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

(Takeda) is pleased to announce that Héma-Québec has added HyQvia ® – (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a replacement ...

The Hyqvia market, showing significant growth in ... A good example is immune globulin infusion, used for treating chronic inflammatory demyelinating polyneuropathy CIDP and primary ...

TORONTO, Jan. 29, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia ® – (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution ...

Halozyme Therapeutics (HALO) announced that Takeda (TAK) received regulatory approval for HYQVIA by the Japanese Ministry of Health, Labour and Welfare, MHLW, for patients with agammaglobulinemia ...